Children with high grade brain tumors will soon be able to receive cutting-edge onocolytic virus therapy.
August 24, 2016
Collaborative Research Funding Helps to Advance Innovative New Treatments for Pediatric Brain Tumors
SKC challenged NICE on their decision to deny children the only drug ever specifically developed against neuroblastoma. SKC provided logical arguments against their assessment of cost and efficacy, and championed the plight of these innocent and vulnerable children.
The 6th Annual Spring Celebration was held on June 8 at 583 Park Avenue in New York City. 300 guests attended the event and helped raise $300,000 during the live auction to create three new clinical trials using combination PD-1 inhibitors for children with deadly brain tumors and neuroblastoma.
Scientists will combine NK cell therapy with an immunocytokine to target children with relapsed or refractory disease including those with bulky tumors.
Now for the first time, scientists will combine NK cell therapy with an immunocytokine to target children with relapsed/refractory disease including those with bulky tumors.
New York City—(October 10, 2013) Researchers have made rapid advances in understandinghow to manipulate the immune system safely to destroy cancer cells. Adoptive transfer ofhaploidentical natural killer (NK) cells has shown promise as a treatment option to target andkill cancer cells in a less toxic way than conventional therapies. Now for the first time, scientists will…